The demand for subcutaneous immunoglobulin (SCIG) therapy has been experiencing notable growth in recent years due to several factors. One significant driver is the increasing prevalence of autoimmune diseases, primary immunodeficiencies, and other conditions that require immunoglobulin replacement therapy. With advancements in medical science leading to better diagnosis and understanding of these conditions, more individuals are being identified as candidates for SCIG therapy, thus contributing to the rising demand.

Moreover, there is a growing trend towards home-based healthcare and patient-centered treatment options. SCIG therapy offers several advantages over traditional intravenous immunoglobulin (IVIG) therapy, including convenience, flexibility, and reduced healthcare costs. As a result, more patients are opting for SCIG therapy administered at home, which has led to an increased demand for SCIG products and related services.

Furthermore, the COVID-19 pandemic has further highlighted the importance of immunoglobulin therapy in managing immune-related conditions. With the pandemic causing disruptions to healthcare systems worldwide and increasing the demand for immunoglobulin products to treat severe cases of COVID-19, there has been heightened awareness of the role of SCIG therapy in supporting immune function and improving patient outcomes. As a result, the demand for SCIG therapy is expected to continue rising as more healthcare providers and patients recognize its benefits in various clinical settings.